Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 193 Lung Neoplasms 79 Pancreatic Neoplasms 47 Neoplasms 30 Non-Squamous Non-Small Cell Lung Cancer 19 Head and Neck Neoplasms 19 Glioblastoma 19 Adenocarcinoma of Lung 19 Squamous Cell Carcinoma of Head and Neck 18 Neoplasm Metastasis 17 Gliosarcoma 17 Brain Neoplasms 17 Breast Neoplasms 15 Rectal Neoplasms 13 Colorectal Neoplasms 13 Adenocarcinoma, Bronchiolo-Alveolar 13 Colonic Neoplasms 12 Carcinoma, Hepatocellular 11 Carcinoma, Renal Cell 10 Glioma 8 Astrocytoma 8 Salivary Gland Neoplasms 7 Gallbladder Neoplasms 7 Esophageal Neoplasms 7 Carcinoma, Ovarian Epithelial 7 Prostatic Neoplasms 6 Ovarian Neoplasms 6 Oligodendroglioma 6 Fallopian Tube Neoplasms 6 Carcinoma, Squamous Cell 6

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡